AAA
VRCA icon

Affinity Asset Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Affinity Asset Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Hold
707,338
– – 0.2% 83
2026
Q1 		$3.74M Hold
707,338
– – 0.19% 83
2025
Q4 		$5.88M Buy
+707,338
New +$3.92M 0.33% 59

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Affinity Asset Advisors's VRCA Position: Q2 2026 in Review

Affinity Asset Advisors held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 707,338 shares worth $4.33M. The position accounts for 0.2% of the portfolio, ranked #83.

Affinity Asset Advisors first reported a position in VRCA in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.88M in Q4 2025. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Affinity Asset Advisors held 707,338 shares of Verrica Pharmaceuticals worth $4.33M as of Q2 2026.
  • Affinity Asset Advisors left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
  • Verrica Pharmaceuticals made up 0.2% of Affinity Asset Advisors's portfolio in Q2 2026, its #83 holding.
  • Affinity Asset Advisors first reported a position in Verrica Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Affinity Asset Advisors's Verrica Pharmaceuticals position peaked at $5.88M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.